Bioenergy Life Sciences received novel food authorization for Bioenergy Ribose from the European Food Safety Authority (EFSA), according to a press release.

Bioenergy Ribose is a 5-carbon monosaccharide that works by helping to regulate the body’s natural energy synthesis, according to the release. It also helps to reduce muscle soreness. It provides “sustainable cellular energy with no crash,” according to a quote in the release from Alex Xue, Ph.D., EVP and chief scientific officer at Bioenergy.

The panel noted that the acceptable level of intake is 36mg/kg of body weight per day, the release says, although the level in dietary supplements exceeds this limit.

The release noted that this is good news for international companies using Bioenergy Ribose in formulations sold in the U.S., as they can now sell those formulas in Europe as well.

Penny Portner, director of marketing at Bioenergy, said in the release: “Achieving a place on the EFSA novel foods list requires a rigorous approval process. This is an important milestone for our company. We are gratified that the panel agreed with the significant science we submitted demonstrating the benefits and safety of Bioenergy Ribose.”

The release notes that the product’s benefits are documented by more than 110 clinical studies. It has achieved GRAS status with a “no questions letter” from FDA.